Technical Analysis for ARWR - Arrowhead Research Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Gapped Up | Strength | 0.00% | |
20 DMA Resistance | Bearish | 9.30% | |
Calm After Storm | Range Contraction | 9.30% | |
Spinning Top | Other | 13.51% | |
Calm After Storm | Range Contraction | 13.51% | |
Down 3 Days in a Row | Weakness | 13.51% | |
Fell Below 20 DMA | Bearish | 13.41% | |
Wide Range Bar | Range Expansion | 13.41% | |
Earnings Movers | Other | 13.41% |
Alert | Time |
---|---|
Up 10% | about 21 hours ago |
60 Minute Opening Range Breakout | about 21 hours ago |
Gap Up Partially Closed | about 23 hours ago |
Rose Above Previous Day's High | about 23 hours ago |
Rose Above 10 DMA | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/09/2024
Arrowhead Research Corporation Description
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Organ Systems Molecular Biology Infection Obesity Hepatitis B Gene Expression RNA Rna Interference Apoptosis Chronic Hepatitis B Virus Chronic Hbv Infection Rna Therapeutics Si RNA Small Interfering Rna
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 39.83 |
52 Week Low | 20.67 |
Average Volume | 1,082,553 |
200-Day Moving Average | 28.29 |
50-Day Moving Average | 25.94 |
20-Day Moving Average | 23.48 |
10-Day Moving Average | 24.08 |
Average True Range | 1.43 |
RSI (14) | 53.27 |
ADX | 18.55 |
+DI | 25.61 |
-DI | 25.93 |
Chandelier Exit (Long, 3 ATRs) | 21.20 |
Chandelier Exit (Short, 3 ATRs) | 25.67 |
Upper Bollinger Bands | 25.74 |
Lower Bollinger Band | 21.22 |
Percent B (%b) | 0.84 |
BandWidth | 19.26 |
MACD Line | -0.54 |
MACD Signal Line | -0.75 |
MACD Histogram | 0.2117 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 27.88 | ||||
Resistance 3 (R3) | 27.62 | 26.42 | 27.40 | ||
Resistance 2 (R2) | 26.42 | 25.70 | 26.55 | 27.24 | |
Resistance 1 (R1) | 25.73 | 25.25 | 26.08 | 25.99 | 27.09 |
Pivot Point | 24.53 | 24.53 | 24.70 | 24.66 | 24.53 |
Support 1 (S1) | 23.84 | 23.81 | 24.19 | 24.10 | 22.99 |
Support 2 (S2) | 22.64 | 23.36 | 22.77 | 22.84 | |
Support 3 (S3) | 21.95 | 22.64 | 22.68 | ||
Support 4 (S4) | 22.21 |